Laurus Labs Peer Comparison

NSE: LAURUSLABS | BSE: 540222

₹2,007.00

₹-19.20 (-0.95%)

As on 25-Sep-2026IST

Market cap

₹1,08,116 Cr

Revenue (TTM)

₹7,270 Cr

P/E Ratio

98.9

P/B Ratio

19.2

Div. Yield

0.1 %

Edit

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	1,08,116	67,254	36,827	27,561	26,810
Revenue (₹ Cr)	7,270	17,737	3,564	1,936	1,462
Net Profit (₹ Cr)	1,090.76	1,797.81	414.00	288.22	387.35
Net Margin (%)	14.89	9.86	11.23	14.79	26.01
RoE (%)	21.64	30.87	8.38	29.77	25.18
Price to Earnings	98.88	37.41	90.04	95.63	69.42
Price-To-Book	19.17	6.14	7.32	20.53	15.54

Income Statement (₹ Cr)

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Operating Revenue	7,269.64	17,736.55	3,564.00	1,935.80	1,461.80
Total Income	7,323.34	18,236.50	3,686.00	1,948.58	1,489.25
Total Expenditure	5,235.79	12,939.86	2,792.00	1,485.56	919.25
EBITDA	2,033.85	4,796.69	772.00	450.24	542.56
Depreciation	487.08	616.73	226.00	50.83	37.68
EBIT	1,546.77	4,179.96	546.00	399.41	504.88
Interest	161.45	204.50	217.00	40.84	3.77
Other Income	53.70	499.94	122.00	12.78	27.45
Exceptional Items	0.00	-1,942.85	12.00	0.00	0.00
Profit before Tax	1,439.02	2,532.56	463.00	371.35	528.56
Provision for Tax	348.26	734.75	49.00	83.14	141.21
Profit after Tax	1,090.76	1,797.81	414.00	288.22	387.35

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	5,300.06	10,512.11	4,940.00	1,288.82	1,653.56
Minority Interest	2.84	0.10	-5.00	0.00	-1.13
Non-Current Liabilities	1,444.40	3,019.66	1,712.00	202.03	42.40
Current Liabilities	3,635.43	6,376.43	1,622.00	835.87	230.82
Total Liabilities	10,511.19	19,906.65	8,578.00	2,326.71	1,983.96

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Non-Current Assets	5,220.48	7,567.18	5,343.00	519.60	1,026.85
Current Assets	4,829.21	11,299.71	2,606.00	1,681.81	881.27
Total Assets	10,511.19	19,906.65	8,578.00	2,326.71	1,983.96
Total Debt*	2,397.49	0.00	2,125.00	259.37	26.49
Net Current Assets	1,193.78	4,923.28	984.00	845.94	650.46
Contingent Liabilities	420.55	787.81	768.26	19.09	17.25

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	1,623.50	3,445.03	390.00	205.05	292.17
Cash Flow from Investing Activities	-1,088.66	-1,283.23	-241.00	-409.72	-265.94
Cash from Financing Activities	-524.72	-2,708.75	-54.00	283.07	4.10
Net Cash Inflow / Outflow	10.12	-546.95	95.00	78.39	30.33

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
ROCE (%)	18.20	20.35	6.79	29.22	32.42
ROE (%)	21.64	30.87	8.38	29.77	25.18
ROA (%)	10.99	10.00	4.94	24.77	21.93
EBIT Margin (%)	21.28	23.57	15.32	20.63	34.54
Net Margin (%)	14.89	9.86	11.23	14.79	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	22.62	32.94	18.37	46.65	40.90
EBIT Growth (%)	87.41	126.49	252.26	62.13	124.50
Net Profit Growth (%)	116.73	138.48	377.85	89.49	104.15
EPS Growth (%)	114.66	174.53	1,001.33	78.60	42.32
Book Value Growth (%)	18.63	18.53	13.47	144.31	26.03

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Price / Earnings	98.50	21.74	92.32	95.12	69.36
Price / Book Value	19.11	6.15	7.31	20.74	15.53
Dividend Yield (%)	0.10	0.10	0.00	0.09	0.08
EV/EBITDA	54.11	13.81	49.55	61.65	49.01
Market Cap (₹ Cr)	53,545.31	60,201.30	19,071.62	12,753.19	20,944.75

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.12	0.00	0.31	0.11	0.02
Short term debt to equity ratio	0.28	--	0.09	0.05	0.02
Current Ratio	1.33	1.77	1.61	2.01	3.82
Quick Ratio	0.68	1.23	1.06	1.14	2.82
Interest Coverage	9.91	13.38	3.13	10.09	141.16

	Laurus Labs	Glenmark Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	29.64	27.98	16.50	26.28	24.80
Asset Turnover	0.73	0.99	0.43	1.66	0.83
Receivable days	111.49	43.78	58.75	40.13	88.98
Inventory Days	114.62	34.05	75.82	60.29	56.04
Payable days	155.13	264.58	186.21	232.47	99.95
Cash Conversion Cycle	70.98	-186.74	-51.64	-132.04	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.